RESUMO
Fibrolipomatous hamartoma is a rare benign congenital overgrowth of fibroadipose tissue in the nerve sheath. While usually affecting the median nerve, the digits of the hands and feet are sometimes affected and may result in macrodactyly, which is referred to as macrodystrophia lipomatosa. We present a rare case of fibrolipomatous hamartoma in a 6-week-old female's foot with macrodactyly and syndactyly and discuss its presentation and radiologic features.
RESUMO
Degeneration of the spine is a normal aspect of aging. The associated changes of spine degeneration seen on imaging are typically asymptomatic. However, distinguishing normal age-related change from symptomatic pathologic change can be challenging owing to the overlap in imaging features. Understanding the general prevalence, timing, and evolution of age-related change can aid in this differentiation and help prevent imaging overdiagnosis and unnecessary workup.
Assuntos
Degeneração do Disco Intervertebral , Envelhecimento/patologia , Humanos , Degeneração do Disco Intervertebral/epidemiologia , Degeneração do Disco Intervertebral/patologia , Imageamento por Ressonância Magnética/métodos , Prevalência , Coluna Vertebral/diagnóstico por imagem , Coluna Vertebral/patologiaRESUMO
Immunotherapy agents for treatment of cancer have been investigated for decades, but effective agents have only recently been identified and are increasingly being used in multiple cancer types. There is growing recognition of adverse side effects in multiple organ systems mediated by dysregulation of the immune system, which can be exacerbated by comorbidities often found in cancer patients such as chronic lung disease, diabetes, and hypertension. As a result, internists and other nononcology clinicians are routinely encountering immunotherapy patients who present with a remarkably wide range of symptoms. Here, we present the radiographic manifestations of common side effects from immunotherapy agents. An accurate diagnosis is critical in these often-complex clinical settings in which the consequences of the underlying cancer and other comorbidities must be distinguished from the variable manifestations of treatment toxicity.
Assuntos
Imunoterapia/efeitos adversos , Neoplasias/terapia , Encefalopatias/etiologia , Encefalopatias/patologia , Cardiopatias/etiologia , Cardiopatias/patologia , Humanos , Imunoterapia/métodos , Pneumopatias/etiologia , Pneumopatias/patologiaRESUMO
Medically unexplained symptoms are ubiquitous in clinical practice. Medical use costs of medically unexplained symptoms are projected at approximately $256 billion per year. When initially seen, these symptoms are often baffling, not only to the patients but also to the physicians who encounter them. Because of this, properly diagnosing them is seen generally as difficult at best, leading to massive overuse of unnecessary testing. Subsequently, their management can be cumbersome. All this burdens the patients with unnecessary costs, financially and emotionally. This primer discusses historical perspectives of these and the changing nomenclature, and outlines how to think about these complex symptoms and neurologic findings that will enable a positive diagnosis rather than a diagnosis of exclusion. We also offer useful heuristic principles of their management so that physician-patient relationships can be better maintained and the quality of life of these patients can be improved by way of some simple, economic approaches.